Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in <i>ALK</i> ‐positive NSCLC-Reference-Cited by-同舟云学术

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK ‐positive NSCLC

Published:2022-02-08 Issue:5 Volume:15 Page:1143-1154
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Gupta Neeraj¹^ORCID,Reckamp Karen L.²,Camidge David R.³,Kleijn Huub J.⁴,Ouerdani Aziz⁴,Bellanti Francesco⁴,Maringwa John⁴,Hanley Michael J.¹^ORCID,Wang Shining¹,Zhang Pingkuan¹,Venkatakrishnan Karthik⁵^ORCID

Affiliation:

1. Takeda Development Center Americas, Inc. Lexington Massachusetts USA

2. Samuel Oschin Cancer Center Cedars‐Sinai Medical Center Los Angeles California USA

3. University of Colorado Cancer Center Aurora Colorado USA

4. Certara Princeton New Jersey USA

5. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13231

Reference26 articles.

1. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

2. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

3. Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

4. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

5. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

2. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor;Clinical Pharmacokinetics;2023-07-26

3. Brigatinib pharmacokinetics in patients with chronic hepatic impairment;Investigational New Drugs;2023-04-13

4. A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors;The Journal of Clinical Pharmacology;2023-01-27

5. Targeted therapy;Medicines for Cancer;2023